使用c-MET抑制剂治疗对EGFR TKI具有耐药性的癌症

• Format: Patent
• Language: Chinese
• Published: 22.07.2025
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

本公开提供了治疗受试者中的癌症的方法。在一个实施方式中，所述方法包括向所述受试者施用治疗有效量的c-Met抑制剂，其中所述受试者已被确定具有c-MET基因扩增和激活性EGFR突变。 The present disclosure provides methods of treating a cancer in a subject. In one embodiment, the method comprises administering to the subject a therapeutic effective amount of a c-Met inhibitor, wherein the subject has been determined to have a c-MET gene amplification and an activating EGFR mutation.